GleamWall
中文EN

DRMA Dermata Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1853816 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-7.4%
TTM EPS YoY-121.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-241.5%
ROA-162.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets41.1%
Debt / equity0.00x
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-10.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$74,137———————
Cost of revenue$34,008———————
Gross profit$40,129———————
R&D expense$143,294$212,563$383,724$526,620$504,387$617,835$1.28M$2.19M
SG&A expense$2.76M$2.80M$1.54M$1.37M$1.26M$1.15M$1.06M$1.01M
Operating income-$2.86M-$3.01M-$1.93M-$1.90M-$1.76M-$1.77M-$2.34M-$3.20M
Net income-$2.82M-$2.97M-$1.85M-$1.86M-$1.69M-$1.70M-$2.30M-$3.15M
EPS (basic)-0.55-0.74-0.48—-1.65-1.22-4.47—
EPS (diluted)-0.55-0.74-0.48—-1.65-1.66-4.47—
Weighted avg. shares (diluted)5.12M4.02M3.86M—1.03M1.03M515,465—
Balance sheet
Cash & equivalents$4.82M$4.41M$6.95M$7.52M$4.66M$6.48M$9.72M$3.16M
Inventory$825,279$149,734$93,091—————
Current assets$6.43M$5.16M—$7.86M————
PP&E, net$158,904$129,367——————
Total assets$6.64M$5.32M$7.47M$7.86M$5.07M$6.64M$10.01M$3.53M
Total liabilities$2.73M$1.83M$1.05M$1.64M$1.11M$1.03M$2.70M$1.97M
Shareholders' equity$3.91M$3.49M$6.41M$6.22M$3.96M$5.61M$7.30M$1.56M
Shares outstanding4.93M4.02M4.02M2.66M844,457637,7576.03M251,725
Cash flow statement
Operating cash flow-$2.65M-$2.42M-$2.48M-$1.33M-$1.80M-$2.69M-$1.93M-$2.91M
Capital expenditure$52,980———————
Free cash flow-$2.70M———————
Investing cash flow-$52,980———————
Financing cash flow$3.31M-$323$1.90M$4.19M-$12,988-$547,857$8.49M-$68,568
Stock-based compensation$42,179$41,780$43,278$29,469$37,840$39,234$37,189$29,815

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.